NCT03919955View on ClinicalTrials.gov

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions
Sleep Apnea
Interventions
DRUG

Atomoxetine

Atomoxetine 80 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.

DRUG

Oxybutynin

Oxybutynin 5 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.

DRUG

Placebo

Placebo, per mouth, before bed.Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03919955 - A Novel Pharmacological Therapy for Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter